Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Hepatology. 2018 Mar 26;67(5):1797–1806. doi: 10.1002/hep.29660

Table 2.

Diabetes and risk of HCC in women (1980–2012) and men (1986–2012) in pooled NHS and HPFS cohorts (n=150,652)

No Diabetes Diabetes
Women

Cases/Person-years 44/3,173,654 25/212,578
Age-adjusted HR (95%CI) 1 5.80 (3.49–9.64)
Model 2; (95%CI) 1 5.61 (3.33–9.45)
Model 3§; HR (95%CI) 1 5.49 (3.16–9.51)

Men

Cases/Person-years 31/1,018,938 12/83,239
Age-adjusted HR (95%CI) 1 3.42 (1.74–6.72)
Model 2; (95%CI) 1 3.28 (1.65–6.50)
Model 3§; HR (95%CI) 1 3.34 (1.64–6.78)

Pooled

Cases/Person-years 75/4,192,592 37/295,818
Age-adjusted HR (95%CI) 1 4.77 (3.18–7.14)
Model 2; (95%CI) 1 4.59 (3.04–6.92)
Model 3§; HR (95%CI) 1 4.59 (2.98–7.07)

Abbreviations: HCC, hepatocellular carcinoma; NHS, Nurses’ Health Study; HPFS, Health Professionals Follow-up Study; PY, person-years; HR, Hazard Ratio; CI, confidence interval

Model 2 = age, race (white vs. non-white) and body mass index (continuous kg/m2), assessed as a time-dependent covariate. The combined analysis was additionally adjusted for sex.

§

Model 3 = Model 2 + alcohol intake (0 – 4.9 g/day, 5–14.9 g/day, ≥15 g/day), smoking status (current vs. prior vs. never), physical activity (< 3 metabolic equivalent (MET)-hours/week, 3 to 8.9 MET-hours/week, ≥ 9 MET-hours/week), regular aspirin use (non-use vs. use of at least 2 aspirin tablets per week), and family history of diabetes (no vs. yes). The combined analysis was additionally adjusted for sex.